Cancers (Nov 2021)

Proteomic Analysis Identifies NDUFS1 and ATP5O as Novel Markers for Survival Outcome in Prostate Cancer

  • Robert Wiebringhaus,
  • Matteo Pecoraro,
  • Heidi A. Neubauer,
  • Karolína Trachtová,
  • Bettina Trimmel,
  • Maritta Wieselberg,
  • Jan Pencik,
  • Gerda Egger,
  • Christoph Krall,
  • Richard Moriggl,
  • Matthias Mann,
  • Brigitte Hantusch,
  • Lukas Kenner

DOI
https://doi.org/10.3390/cancers13236036
Journal volume & issue
Vol. 13, no. 23
p. 6036

Abstract

Read online

We aimed to identify novel markers for aggressive prostate cancer in a STAT3-low proteomics-derived dataset of mitochondrial proteins by immunohistochemical analysis and correlation with transcriptomic data and biochemical recurrence in a STAT3 independent PCa cohort. Formalin-fixed paraffin-embedded tissue (FFPE) sample selection for proteomic analysis and tissue-microarray (TMA) generation was conducted from a cohort of PCa patients. Retrospective data analysis was performed with the same cohort. 153 proteins differentially expressed between STAT3-low and STAT3-high samples were identified. Out of these, 46 proteins were associated with mitochondrial processes including oxidative phosphorylation (OXPHOS), and 45 proteins were upregulated, including NDUFS1/ATP5O. In a STAT3 independent PCa cohort, high expression of NDUFS1/ATP5O was confirmed by immunocytochemistry (IHC) and was significantly associated with earlier biochemical recurrence (BCR). mRNA expression levels for these two genes were significantly higher in intra-epithelial neoplasia and in PCa compared to benign prostate glands. NDUFS1/ATP5O levels are increased both at the mRNA and protein level in aggressive PCa. Our results provide evidence that NDUFS1/ATP5O could be used to identify high-risk PCa patients.

Keywords